Nisa Investment Advisors
NBSE

Nisa Investment Advisors’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Nisa Investment Advisors’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-330
Closed -$50K – 2374
2020
Q3 		$50K Buy
+330
New +$53.8K ﹤0.01% 1811

Other funds holding NBSE

GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
FWM
Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return

Nisa Investment Advisors's NBSE Position: Q4 2020 in Review

Nisa Investment Advisors sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q4 2020, closing a stake of 330 shares — an estimated $50K sold.

Nisa Investment Advisors first reported a position in NBSE in Q3 2020 and held it in 1 quarter. The position peaked at $50K in Q3 2020. 53 funds tracked by Wall St. Rank hold NBSE as of Q4 2020.

  • Nisa Investment Advisors reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Nisa Investment Advisors sold 330 NeuBase Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $50K.
  • Nisa Investment Advisors first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q3 2020 and held it in 1 quarter.
  • Nisa Investment Advisors's NeuBase Therapeutics, Inc. Common Stock position peaked at $50K in Q3 2020.
  • 53 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Nisa Investment Advisors's 13F filing for Q4 2020, filed 25 Jan 2021.